Intervacc (IVACC) Stock Overview
Develops novel veterinary vaccines for animals in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IVACC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Intervacc AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.66 |
| 52 Week High | SEK 1.35 |
| 52 Week Low | SEK 0.57 |
| Beta | 0.37 |
| 1 Month Change | -24.43% |
| 3 Month Change | -26.78% |
| 1 Year Change | -36.63% |
| 3 Year Change | -94.19% |
| 5 Year Change | -99.16% |
| Change since IPO | -91.44% |
Recent News & Updates
Recent updates
Intervacc (STO:IVACC) Is In A Good Position To Deliver On Growth Plans
Dec 15
We Think Intervacc (STO:IVACC) Can Afford To Drive Business Growth
Aug 31Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?
Jun 08We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate
Oct 11We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully
Feb 26We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate
Sep 03We're Not Worried About Intervacc's (STO:IVACC) Cash Burn
Apr 28Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation
Dec 15It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers
Jun 01We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth
May 17Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling
Feb 28We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth
Feb 01When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?
Jan 06Shareholder Returns
| IVACC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 6.1% | -3.3% | -3.8% |
| 1Y | -36.6% | 7.2% | 3.8% |
Return vs Industry: IVACC underperformed the Swedish Biotechs industry which returned 5% over the past year.
Return vs Market: IVACC underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| IVACC volatility | |
|---|---|
| IVACC Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IVACC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IVACC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 15 | Carl-Johan Dalsgaard | intervacc.se |
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.
Intervacc AB (publ) Fundamentals Summary
| IVACC fundamental statistics | |
|---|---|
| Market cap | SEK 224.60m |
| Earnings (TTM) | -SEK 80.81m |
| Revenue (TTM) | SEK 20.09m |
Is IVACC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVACC income statement (TTM) | |
|---|---|
| Revenue | SEK 20.09m |
| Cost of Revenue | SEK 31.57m |
| Gross Profit | -SEK 11.49m |
| Other Expenses | SEK 69.33m |
| Earnings | -SEK 80.81m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 14, 2026
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -57.18% |
| Net Profit Margin | -402.32% |
| Debt/Equity Ratio | 0.03% |
How did IVACC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 13:39 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intervacc AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Klas Palin | DNB Carnegie Commissioned Research |